BASKING RIDGE, N.J., Sept. 08, 2016 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (NASDAQ: CLBS ) (“Caladrius” or the “Company”), a cell therapy company combining an industry-leading development and manufacturing services provider (PCT) with a select therapeutic development pipeline, announces today that the Company’s leadership and experts will present at the following upcoming September conferences:
Baylor College of Medicine Cardiology Fellowship Program, Grand Rounds
- Date and Time: Friday, September 16, 2016, 12:00 PM CT
- Venue: CHI St. Luke’s Health, Home of The Texas Heart Institute, Houston, Texas
- Topic: Getting Back to Normal: Cell-Based Therapies to Reverse Disease and Restore Health
- Presenter: Douglas W. Losordo, MD, Senior Vice President Clinical, Medical and Regulatory Affairs and Chief Medical Officer of Caladrius
Regulatory Affairs Professional Society’s Regulatory Convergence
- Date and Time: Monday, September 19, 2016, 4:00 PM PT
- Website: http://www.raps.org/2016
- Venue: The San Jose Convention Center, San Jose, California
- Session : Global Developments in Cell and Gene Therapy
- Topic: Japan’s New Regenerative Medicine Law: What to Expect on Your Way to an Approved CTN
- Presenter: William Sietsema, PhD, Executive Director, Global Regulatory Affairs of Caladrius
2016 Aegis Growth Conference
- Date and Time: Wednesday, September 21, 2016, 10:00 AM PT
- Website: http://www.meetmax.com/sched/event_37061/~pub...t_id=37061
- Venue: The Encore at Wynn, Las Vegas, Nevada
- Topic: Company Presentation
- Presenter: David J. Mazzo, PhD, Chief Executive Officer, Caladrius
Phacilitate Leaders Cell & Gene Therapy Europe
- Website: http://www.cgteurope.com/
- Venue: Maratim Proarte Hotel, Berlin, Germany
- Panel Topic #1: Presenting a vision for the future industrialization of ATMPs in Europe
- Panelist: Cenk Sumen, PhD, Manager, Technology & Business Development, PCT, a Caladrius Company
- Date and Time: Wednesday, September 21, 2016, 5:45 PM CET
- Panel Topic #2: Critical Quality Attributes: Essential Elements of Single-Use for Scalable Manufacturing of Cell Therapies
- Panelist: Cenk Sumen, PhD, Manager, Technology & Business Development, PCT, a Caladrius Company
- Date and Time: Thursday, September 22, 2016, 10:25 AM CET
- Panel Topic #3: How are the world’s modified T cell immunotherapy leaders gearing up for market in Europe?
- Panel Chair: Cenk Sumen, PhD, Manager, Technology & Business Development, PCT, a Caladrius Company
- Date and Time: Thursday, September 22, 2016, 12:05 PM CET
International Society of Cell Therapy (ISCT) North America Regional Meeting 2016
- Date and Time: Friday, September 30, 2016, 12:30 PM CT
- Website: http://www.isct-na2016.com
- Venue: The Peabody, Memphis, Tennessee
- Panel: Tutorial on Materials and Cell Therapy, Sponsored by Saint-Gobain
- Panelist: David Smith, PhD, Biomedical Engineer, Center for Innovation and Engineering, PCT, a Caladrius Company
About Caladrius Biosciences
Caladrius Biosciences, Inc., through its subsidiary, PCT, is a leading development and manufacturing partner to the cell therapy industry. PCT works with its clients to overcome the fundamental challenges of cell therapy manufacturing by providing a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage and distribution, as well as expert consulting and regulatory support. PCT and Hitachi Chemical Co., Ltd. have entered into a strategic global collaboration to accelerate the creation of a global commercial cell therapy development and manufacturing enterprise with deep engineering expertise. Around the core expertise of PCT, Caladrius strategically develops select product candidates, which currently includes an innovative therapy for type 1 diabetes based on a proprietary platform technology for immunomodulation. For more information, visit www.caladrius.com .
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. All statements other than statements of historical fact contained in this press release are forward-looking statements. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the “Risk Factors” described in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 15, 2016, and in the Company’s other periodic filings with the SEC. The Company’s further development is highly dependent on, among other things, future medical and research developments and market acceptance, which are outside of its control.
CONTACTS: Investors: LHA Anne Marie Fields Senior Vice President Phone: +1-212-838-3777 Email: afields@lhai.com Media: Caladrius Biosciences, Inc. Eric Powers Director, Communications and Marketing Phone: +1-212-584-4173 Email: epowers@caladrius.com
